| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| Cloned are two novel VIP receptor ( VIPR ) mRNAs ( VIPR 1 and VIPR 2 ) that also bind a second neurokine called pituitary adenylated cyclase activating polypeptide ( PACAP ) . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| Both VIP R 1 and VIP R 2 , which express high affinity for VIP and related neuropeptides such as the pituitary adenylate cyclase activating peptide ( PACAP ) , are present on lymphocyte subsets , and recent reports suggest that whereas VIP R 1 is expressed constitutively , VIP R 2 expression is induced upon lymphocyte activation . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| Two distinct receptors for VIP , the VIP receptor type 1 ( VIPR 1 ) and the VIP receptor type 2 ( VIPR 2 ) , have recently been cloned , each of which binds PACAP and VIP with equal affinity . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| In contrast , VPAC 1 and VPAC 2 , which bind with the same affinity PACAP and VIP , are mainly coupled to the adenylyl cyclase pathway . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| Three receptor subtypes for the neuropeptides vasoactive intestinal peptide ( VIP ) and pituitary adenylate cyclase activating polypeptide ( PACAP ) have been identified in mammals : the PAC 1 receptor ( PAC 1 R ) which is selectively activated by PACAP , and two VPAC receptors ( VPAC 1 R and VPAC 2 R ) , which are equally stimulated by PACAP and VIP . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| Since vasoactive intestinal polypeptide ( VIP ) and pituitary adenylate cyclase activating polypeptide ( PACAP ) are up regulated in dorsal root ganglion cells following peripheral nerve injury , we investigated the expression and influence of VPAC 1 , VPAC 2 and PAC 1 receptors in rat spinal dorsal horn following a chronic constriction injury ( CCI ) . ^^^ Ionophoresis of selective agonists for the receptor subtypes revealed that the VPAC 2 receptor agonist excited twice as many cells in CCI compared to normal animals , while the number of cells excited by the VPAC 1 receptor agonist decreased and responses to PACAP 38 remained unchanged . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| VPAC 1 , the type 1 VIP receptor , which is constitutively expressed in macrophages , and to a lesser degree VPAC 2 , the type 2 VIP receptor , which is induced upon macrophage activation , mediate the effect of VIP / PACAP . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| Using the reverse transcription polymerase chain reaction , we found mRNA expression of PAC 1 ( PACAP HOP variant ) and VPAC 2 in neurons , PAC 1 ( PACAP R variant ) , VPAC 1 and VPAC 2 in astrocytes . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| Domains determining agonist selectivity in chimaeric VIP 2 ( VPAC 2 ) / PACAP ( PAC 1 ) receptors . 1 The VPAC 2 and PAC 1 receptors are closely related members of the Group 2 G protein coupled receptor family . ^^^ At the VPAC 2 receptor , VIP is equipotent to PACAP 38 in stimulating cyclic AMP production , whereas at the PAC 1 receptor PACAP 38 is many fold more potent than VIP . ^^^ In this study , domains which confer this selectivity were investigated by constructing four chimaeric receptors in which segments of the VPAC 2 receptor were exchanged with the corresponding segment from the PAC 1 receptor . 2 When expressed in COS 7 cells all the chimaeric receptors bound the common ligand [ 125I ] PACAP 27 and produced cyclic AMP in response to agonists . 3 Relative selectivity for agonists was determined primarily by the amino terminal extracellular domain of the PAC 1 receptor and the VPAC 2 receptor . ^^^ The interchange of other domains had little effect on the potency of PACAP 38 or PACAP 27 . 4 For chimaeric constructs with a PAC 1 receptor amino terminal domain , the substitution of increasing portions of the VPAC 2 receptor decreased the potency of VIP yet increased that of helodermin . 5 This suggests that the interaction of VIP / helodermin but not PACAP with the PAC 1 receptor may be influenced ( and differentially so ) by additional receptor domains . . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| Here we investigate the expression of specific PACAP receptors ( PAC 1 ) and common VIP / PACAP receptors ( VPAC 1 and VPAC 2 ) in the human hyperplastic prostate by immunological methods . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| VIP / PACAP mediated inhibition of both AICD and FasL expression is mediated through the specific receptors VPAC 1 and VPAC 2 . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| Pancreatic beta cells express two PACAP receptor subtypes , a PACAP preferring ( PAC 1 ) and a VIP shared ( VPAC 2 ) receptor . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| Molecular cloning of PACAP receptors has shown the existence of three distinct receptor subtypes , the PACAP specific PAC 1 receptor , which is coupled to several transduction systems , and the two PACAP / VIP indifferent VPAC 1 and VPAC 2 receptors , which are primarily coupled to adenylyl cyclase . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| The VIP / PACAP receptor subtypes VPAC 1 , VPAC 2 , and PAC 1 were evaluated in these tissues by determining the rank order of potencies of VIP and PACAP as well as VPAC 1 and VPAC 2 selective analogues . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| PACAP exerts these activities by binding to PACAP selective ( PAC 1 ) or nonselective ( VPAC 1 , VPAC 2 ) receptors ( R ) . ^^^ The present report demonstrates a distinct spatiotemporal regulation of PACAP , PAC 1 R , VPAC 1 R , and VPAC 2 R expression in primary cultured rat astrocytes . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| In the somatolactotrope GH4C1 cell line , these effects are mediated through the type 2 like PACAP receptor ( VPAC 2 ) coupled to the cAMP pathway . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| The VIP but not the PACAP induced potentiation of ACh evoked currents was inhibited by [ Ac Tyr 1 , D Phe 2 ] GRF 1 29 , amide ( 100 nM ) , a selective antagonist of VPAC 1 and VPAC 2 receptors ; whereas the PACAP 38 but not the VIP induced potentiation was inhibited by 100 nM PACAP 6 38 , a PAC 1 and VPAC 2 receptor antagonist . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| Biologic actions of VIP are exerted through two receptors , VPAC 1 and VPAC 2 , having similar binding affinity for both VIP and PACAP . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| The modulating effects of VIP on excitotoxin induced heterotopias were mimicked by forskolin , PACAP , and by a specific VPAC 2 receptor agonist but not by a VPAC 1 agonist , and were blocked by a protein kinase A ( PKA ) inhibitor . ^^^ Taken together , these data suggest that VIP and PACAP can attenuate ibotenate induced heterotopias in newborn hamster and that this effect is mediated by the VPAC 2 receptor utilizing the cAMP PKA pathway . . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| Pharmacological characterization of intestinal VIP / PACAP receptors indicates the existence of receptors , such as a PACAP 27 preferring receptor and a VIP specific receptor , distinct from those that have been cloned ( VPAC 1 , VPAC 2 , and PAC 1 ) . . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| Reverse transcription polymerase chain reaction experiments , together with pharmacological approaches with a set of specific agonists and antagonists , demonstrated the presence of the three VIP / PACAP receptor subtypes ( PAC 1 , VPAC 1 , and VPAC 2 with a major role for VPAC 1 , acting through adenylate cyclase ( AC ) stimulation . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| Pituitary adenylate cyclase activating polypeptide ( PACAP ) is a basic 38 amino acid peptide , which acts through three main G protein coupled VIP / PACAP receptor subtypes , called PAC 1 , VPAC 1 and VPAC 2 . ^^^ RT PCR and quantitative autoradiography , using [ ( 125 ) 1 ] PACAP and selective VIP / PACAP receptor ligands , demonstrated the expression of PAC 1 only in AM , and VPAC 1 and VPAC 2 in both AM and zona glomerulosa ( ZG ) , PACAP receptor expression being absent in zona fasciculata / reticularis ( ZF / R ) . ^^^ Collectively , our findings allow us to conclude that in the rat adrenals : 1 ) PACAP biosynthesis exclusively occurs in the AM ; 2 ) ZG cells are provided with functional VPAC 1 and VPAC 2 receptors , whose activation by PACAP evokes a moderate aldosterone response ; 3 ) AM cells possess all the subtypes of VIP / PACAP receptors , whose activation by PACAP elicits a marked catecholamine response ; and 4 ) PAC 1 receptors are coupled to the AC dependent cascade , VPAC 1 receptors to both the AC and PLC dependent cascades , and VPAC 2 receptors exclusively to the PLC dependent cascade . . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| The effects of a ( N stearyl , Norleucine 17 ) vasoactive intestinal peptide hybrid ( ( SN ) VIPhybrid ) on cells stably transfected with VPAC , , VPAC 2 , or PAC 1 receptors were investigated . ( SN ) VIPhybrid inhibited specific 125I VIP binding to membranes derived from CHO cells transfected with VPAC , or VPAC 2 receptors with high affinity ( IC 50 = 30 and 50 nM ) . ( SN ) VIPhyb inhibited specific 125I PACAP 27 binding to membranes derived from NIH / 3T3 cells transfected with PAC 1 receptors with high affinity ( IC 50 = 65 nM ) . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| Pituitary adenylate cyclase activating peptide ( PACAP ) and vasoactive intestinal peptide ( VIP ) activate two shared receptors , VPAC 1 and VPAC 2 . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| We now report that mice carrying a null mutation of the VPAC ( 2 ) receptor for VIP and PACAP ( Vipr 2 ( / ) ) are incapable of sustaining normal circadian rhythms of rest / activity behavior . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| The use of selective agonists and antagonists of VIP / PACAP receptors showed that type 1 VIP receptor ( VPAC 1 ) is the major receptor involved , but the type 2 VIP receptor ( VPAC 2 ) may be also implicated . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| The actions of PACAP and VIP appear to be mediated by PAC 1 receptors because their effects were suppressed by an antagonist that binds to PAC 1 and VPAC 2 receptors ( PACAP 6 38 ) , but not by an antagonist that binds to the VPAC 1 and VPAC 2 receptors . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| VIP and PACAP are two prominent neuropeptides which share two common G protein coupled receptors VPAC 1 and VPAC 2 while PACAP has an additional specific receptor PAC 1 . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| PACAP binds to a PACAP specific receptor ( PAC 1 ) and to VPAC receptors ( VPAC 1 and VPAC 2 ) , which share high affinity for vasoactive intestinal polypeptide ( VIP ) . ^^^ In the present study , the molecular expression of PACAP receptor isoforms and the signaling pathways involved in the insulin secretory effect of PACAP were investigated in isolated rat and mouse pancreatic islets . mRNA encoding PAC 1 short , hop , and very short variants , as well as VPAC 1 and VPAC 2 , were expressed in pancreatic islets . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| The distribution of mRNA for pituitary adenylate cyclase activating polypeptide ( PACAP ) type 1 ( PAC 1 ) and vasoactive intestinal polypeptide ( VIP ) types 1 and 2 ( VPAC 1 and VPAC 2 , respectively ) receptors was examined by reverse transcriptase polymerase chain reaction ( RT PCR ) in human cerebral arteries and in trigeminal , otic , sphenopalatine and superior cervical ganglia . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| PACAP can exert its effects via VPAC 1 , VPAC 2 and PAC 1 G protein coupled receptors . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| The characterization of the subtype of PACAP / VIP receptors by RT PCR analysis revealed that PAC 1 receptor mRNA is dominantly present in the myocytes , but VPAC 2 receptor mRNA is abundant in the nonmyocytes . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| When the melanophores were transfected with complementary DNA ( cDNA ) from the three different members of the PACAP receptor family , maxadilan induced pigment dispersion specifically and cAMP accumulation in melanophores transfected with the cDNA for PAC 1 receptors but not VPAC 1 or VPAC 2 receptors . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| PACAP exerts its actions via three heptahelical G protein linked receptors : one PACAP specific ( PAC 1 ) receptor and two receptors ( VPAC 1 and VPAC 2 ) shared with VIP . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| Pituitary adenylate cyclase activating peptide ( PACAP ) has a specific receptor PAC 1 and shares two receptors VPAC 1 and VPAC 2 with vasoactive intestinal peptide ( VIP ) . ^^^ To generate a large pool of VPAC 2 selective agonists for the treatment of type 2 diabetes , structure activity relationship studies were performed on PACAP , VIP , and a VPAC 2 selective VIP analog . ^^^ C terminal extension with the KRY sequence from PACAP 38 led to potent VPAC 2 agonists with improved selectivity ( 100 1000 fold ) . ^^^ Saturation mutagenesis at positions 19 , 27 , 29 , and 30 of VIP and charge scanning mutagenesis of PACAP 27 generated additional VPAC 2 selective agonists . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| VIP and PACAP are two prominent neuropeptides that share two common G protein coupled receptors , VPAC 1 and VPAC 2 , while PACAP has an additional specific receptor , PAC 1 . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| By contrast , our studies of mice lacking the VPAC 2 receptor , which responds to both PACAP and VIP , indicate that this receptor plays a critical role in rhythm generation in the SCN . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| Three distinct receptors mediate the biological effects of PACAP : VPAC 1 and VPAC 2 receptors binding with the same affinity for PACAP and vasoactive intestinal peptide and PAC 1 receptors showing high selectivity for PACAP . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| LC and the LC like cell line XS 106 express mRNA for the pituitary adenylate cyclase activating polypeptide ( PACAP ) receptors VPAC 1 and VPAC 2 . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| VIP and PACAP share two common receptors ( VPAC 1 and VPAC 2 receptors ) while only PACAP binds with high affinity to PAC 1 receptors . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| To examine the distributions of VIP / PACAP receptors ( VPAC 1 , VPAC 2 , and PAC 1 receptors ) in the brain and to identify the cell types that express these receptors , we performed immunohistochemistry and double immunofluorescence in the rat brain with specific antibodies . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| In conclusion , VIP , PACAP and the VPAC 2 receptor may all contribute to the regulation of ADNP gene expression in the developing astrocyte . . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| Cytosolic Ca2+ responses to sub picomolar and nanomolar PACAP in pancreatic beta cells are mediated by VPAC 2 and PAC 1 receptors . ^^^ We measured [ Ca2+ ] 1 in beta cells and examined comparative effects of PAC 1 R selective agonist maxadilan , its antagonist M 65 , VPAC 2 R selective agonist Ro 25 1553 , and native ligands of PACAP and VIP . ^^^ The results suggest that VPAC 2 R and PAC 1 R contribute equally to [ Ca2+ ] 1 responses to sub picomolar concentrations of PACAP , while PAC 1 R has greater contribution to [ Ca2+ ] 1 responses to nanomolar concentrations of this peptide . . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| The expressions of mRNAs for pituitary adenylate cyclase activating polypeptide ( PACAP ) , vasoactive intestinal peptide ( VIP ) , and their receptors ( PAC 1 , VPAC 1 and VPAC 2 ) were examined in the five steps of the in vitro neuronal culture model of embryonic stem ( ES ) cell differentiation . mRNAs for PACAP , VIP , PAC 1 receptor , and VPAC 2 receptor were moderately expressed in neural stem cell enriched cultures , while VPAC 1 receptor mRNA was most prominently expressed in embryoid bodies ( EBs ) . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| Here , we developed and characterized a panel of antipeptide antibodies to the carboxyl terminal regions of the VIP / PACAP receptor subtypes vasoactive intestinal peptide receptor ( VPAC ) 1 , VPAC 2 , and pituitary adenylate cyclase activating peptide receptor ( PAC ) 1 . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| The purpose of this study was to determine whether all D vasoactive intestinal peptide ( VIP ) , an inactive optical isomer of L VIP , modulates the vasorelaxant effects of human L VIP and pituitary adenylate cyclase activating peptide ( PACAP ) 1 38 , two ubiquitous and pleiotropic neuropeptides that activate VPAC 1 and VPAC 2 , two VIP subtype receptors , in the intact peripheral microcirculation . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| In the last decade , it has been demonstrated that vasoactive intestinal peptide ( VIP ) and pituitary adenylate cyclase activating polypeptide ( PACAP ) are two endogenous immunopeptides , which together with three G protein coupled receptors ( VPAC 1 , VPAC 2 , and PAC 1 ) exert a significant , therapeutic effect attenuating the deleterious consequences of septic shock by balancing pro and anti inflammatory factors . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| We performed RT PCR analysis to assess the expression of VIP receptor ( VPAC 1 , VPAC 2 and PAC 1 ) mRNA in normal prostate epithelial and stromal cells and prostate cancer cells , and investigated the effect of VIP and PACAP on the production of IL 6 . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| PACAP binds to PACAP ( PAC 1 ) and vasoactive intestinal peptide preferring receptors ( VPAC 1 , VPAC 2 ) . ^^^ Pretreatment with VPAC 1 and VPAC 2 inhibitors blocked both PACAP and progesterone ( P ) induced receptivity . ^^^ Antisense ( AS ) oligonucleotides to PAC 1 ( not VPAC 1 or VPAC 2 ) inhibited the behavioral effect of PACAP and P . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| Pituitary adenylate cyclase activating protein ( PACAP ) and its structurally related vasointestinal peptide ( VIP ) bind to three G protein coupled receptors named VPAC 1 and VPAC 2 for VIP / PACAP receptors and PAC 1 for PACAP preferred receptors . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| Their biological effects are mediated by specific receptors , VPAC 1 and VPAC 2 , which have comparable affinity for VIP and PACAP , and PAC 1 , which binds VIP with 1 , 000 fold lower affinity than PACAP . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| PURPOSE : To examine pituitary adenylate cyclase activating polypeptide ( PACAP ) receptors ( PAC 1 , VPAC 1 , and VPAC 2 ) mRNA and the effect of PACAP on interleukin 6 ( IL 6 ) , interleukin 8 ( IL 8 ) , and monocyte chemotactic protein 1 ( MCP 1 ) expression in human retinal pigment epithelial cell line ( ARPE 19 ) stimulated with interleukin 1beta ( IL 1beta ) . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| Vasoactive intestinal polypeptide ( VIP ) and pituitary adenylate cyclase activating polypeptide ( PACAP ) are two immunopeptides with anti inflammatory properties exerted through type 1 and 2 VIP receptors ( VPAC 1 and VPAC 2 , respectively ) , and PACAP receptor ( PAC 1 ) . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| Two VIP receptors , shared with a similar affinity by pituitary adenylate cyclase activating polypeptide ( PACAP ) , have been cloned : VPAC 1 and VPAC 2 . ^^^ VIP effects were mimicked with a similar potency by VPAC 2 agonists and PHI but not by VPAC 1 agonists , PACAP 27 or PACAP 38 . ^^^ The pharmacology of this VPAC 2 receptor seems unconventional as PACAP does not mimic VIP effects and PHI acts with a comparable potency . . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| Pituitary adenylate cyclase activating polypeptide ( PACAP ) and vasoactive intestinal peptide ( VIP ) exert their actions via common receptors , VPAC 1 and VPAC 2 , which are equally sensitive to both peptides , while PACAP stimulates its specific PAC 1 type receptors . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| Three distinct receptor subtypes , with differing affinity for VIP , have been cloned and characterized as receptors 1 and 2 ( VPAC 1 and VPAC 2 ) and pituitary adenylate cyclase activating polypeptide receptor ( PAC 1 ) . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| Structural and functional identification of the pituitary adenylate cyclase activating polypeptide receptor VPAC 2 from the frog Rana tigrina rugulosa . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| Vasoactive intestinal peptide ( VIP ) and pituitary adenylate cyclase activating peptide ( PACAP ) bind similarly to VPAC 1 and VPAC 2 receptors , whereas PACAP binds with higher affinity than VIP to PAC 1 receptors . ^^^ PAC 1 , VPAC 1 and VPAC 2 receptors were functional , as shown by their coupling to adenylate cyclase stimulation : VIP , PACAP 27 and PACAP 38 behaved similarly at this level , whereas both VPAC receptors acted alike as shown by means of specific peptide agonists and antagonists . ^^^ |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P18509 and P41587 |
Pubmed |
SVM Score :0.0 |
| NA |
|